EMP-01 (R-MDMA) AS A NEXT-GENERATION ENTACTOGEN: MECHANISTIC RATIONALE AND THERAPEUTIC POTENTIAL IN SOCIAL ANXIETY DISORDER

The purpose of this presentation is to review mechanistic and clinical evidence supporting entactogen-mediated modulation of social threat and social reward systems in Social Anxiety Disorder and to outline the clinical development strategy for EMP01. SAD is a highly prevalent, chronic, fear-based condition involving heightened social threat sensitivity, reduced social reward, impaired social learning and accompanied by persistent avoidance that restricts functioning. Current treatments are only partially effective and often leave these interpersonal fear structures insufficiently addressed. Entactogens— including racemic MDMA and next-generation R-MDMA–derived therapeutics—produce acute prosocial states, including increased emotional openness, self-compassion, and social approach behavior while reducing negative responses to rejection. Rather than producing stimulant-like activation, R-MDMA produces a more introspective experience that may support reprocessing of maladaptive schemas. Preliminary clinical evidence from a pilot RCT of racemic MDMA in patients with SAD supports entactogenic mechanisms (Danforth et al., 2018). It yielded large, durable LSAS reductions and improved interpersonal functioning. Regarding the putative mechanisms underlying the therapeutic efficacy of MDMA, preclinical studies have shown that MDMA can reopen a serotonergic and oxytocindependent critical period of social reward learning (Nardou et al., 2019), which may reduce social withdrawal and shame. And studies of racemic and R-MDMA have shown they can facilitate extinction of fear learning. Human neuroimaging studies elucidating the neurobiological targets of MDMA show that it modulates thalamocortical signaling— enhancing top-down cortical influence and reducing bottom-up threat-related thalamic drive to the insula and ACC—thereby altering sensory, interoceptive, and social evaluative networks implicated in SAD. Theoretical models propose that MDMA modulates affective and cognitive systems underlying social dysfunction by reducing shame and social threat, enhancing affiliative motivation, increasing cognitive flexibility, and supporting corrective social learning. Together these mechanisms align closely with core SAD pathophysiology and provide a strong rationale for entactogenic therapeutics, especially entactogens with an improved safety profile for patients relative to racemic MDMA. EMP-01 is an R-MDMA derivative currently in development to preserve these prosocial and entactogenic properties of racemic MDMA while improving tolerability and reducing physiologic burden. In our Phase 1 first-in-human study, EMP-01 was safe and well tolerated across ascending doses and produced dose-dependent prosocial states - including increased openness, emotional breakthroughs, oceanic boundlessness and interpersonal insight. These results support EMP01’s potential to modulate social threat circuits and enhance adaptive social learning in SAD. Data from the ongoing Phase 2a randomized, placebo-controlled clinical trial of EMP-01 in 60 SAD patients are not yet available; however, late-breaking findings are anticipated for the 2026 ASCP meeting. Together, these mechanistic and clinical findings highlight entactogens as a promising new therapeutic class for conditions characterized by interpersonal fear and maladaptive social learning. EMP-01 represents the first R-MDMA–derived compound to enter Phase 2 testing for SAD, advancing the field by offering a potentially safer, more tolerable entactogenic approach.

References

Nardou R, Lewis EM, Rothhaas R, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019;569(7754):116-120. Danforth AL, Grob CS, Struble C, et al. MDMA-assisted therapy for social anxiety in autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology. 2018;235(11):3137-3148.